|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M,
et al: NCCN guidelines® insights: Non-small cell lung
cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller M and Hanna N: Advances in systemic
therapy for non-small cell lung cancer. BMJ. 375:n23632021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu J and Lin Z: Non-small cell lung cancer
targeted therapy: Drugs and mechanisms of drug resistance. Int J
Mol Sci. 23:150562022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rhodin KE, Rucker AJ, Ready NE, D'Amico TA
and Antonia SJ: The immunotherapeutic landscape in non-small cell
lung cancer and its surgical horizons. J Thorac Cardiovasc Surg.
159:1616–1623. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ganti AK, Klein AB, Cotarla I, Seal B and
Chou E: Update of incidence, prevalence, survival, and initial
treatment in patients with non-small cell lung cancer in the US.
JAMA Oncol. 7:1824–1832. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadeghirad H, Bahrami T, Layeghi SM,
Yousefi H, Rezaei M, Hosseini-Fard SR, Radfar P, Warkiani ME,
O'Byrne K and Kulasinghe A: Immunotherapeutic targets in non-small
cell lung cancer. Immunology. 168:256–272. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Neill TJ, Tofaute MJ and Krappmann D:
Function and targeting of MALT1 paracaspase in cancer. Cancer Treat
Rev. 117:1025682023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gomez Solsona B, Schmitt A,
Schulze-Osthoff K and Hailfinger S: The paracaspase MALT1 in
cancer. Biomedicines. 10:3442022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurden-Pekmezci A, Cakiroglu E, Eris S,
Mazi FA, Coskun-Deniz OS, Dalgic E, Oz O and Senturk S: MALT1
paracaspase is overexpressed in hepatocellular carcinoma and
promotes cancer cell survival and growth. Life Sci. 323:1216902023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan H, Xie Y, Zhang X, Wu S, Zhao H, Wu J,
Wang W and Lin C: Integrative analysis of MALT1 as a potential
therapeutic target for prostate cancer and its immunological role
in pan-cancer. Front Mol Biosci. 8:7149062021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Konczalla L, Perez DR, Wenzel N,
Wolters-Eisfeld G, Klemp C, Lüddeke J, Wolski A, Landschulze D,
Meier C, Buchholz A, et al: Biperiden and mepazine effectively
inhibit MALT1 activity and tumor growth in pancreatic cancer. Int J
Cancer. 146:1618–1630. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan D, Jiang C, Ma Z, Blonska M, You MJ
and Lin X: MALT1 is required for EGFR-induced NF-κB activation and
contributes to EGFR-driven lung cancer progression. Oncogene.
35:919–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dimitrakopoulos FD, Kottorou AE, Kalofonou
M and Kalofonos HP: The fire within: NF-κB involvement in non-small
cell lung cancer. Cancer Res. 80:4025–4036. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fontan L, Yang C, Kabaleeswaran V, Volpon
L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R,
Yang SN, et al: MALT1 small molecule inhibitors specifically
suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 22:812–824.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Yue C, Shi L, Liu G, Cao Q, Shan Q,
Wang Y, Chen X, Li H, Wang J, et al: MALT1 is a potential
therapeutic target in glioblastoma and plays a crucial role in
EGFR-induced NF-κB activation. J Cell Mol Med. 24:7550–7562. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saba NS, Wong DH, Tanios G, Iyer JR,
Lobelle-Rich P, Dadashian EL, Liu D, Fontan L, Flemington EK,
Nichols CM, et al: MALT1 inhibition is efficacious in both naïve
and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Res.
77:7038–7048. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsieh KY, Wei CK and Wu CC: YC-1 prevents
tumor-associated tissue factor expression and procoagulant activity
in hypoxic conditions by inhibiting p38/NF-κB signaling pathway.
Int J Mol Sci. 20:2442019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qian R, Niu X, Wang Y, Guo Z, Deng X, Ding
Z, Zhou M and Deng H: Targeting MALT1 suppresses the malignant
progression of colorectal cancer via miR-375/miR-365a-3p/NF-κB
axis. Front Cell Dev Biol. 10:8450482022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsui KH, Chang KS, Sung HC, Hsu SY, Lin
YH, Hou CP, Yang PS, Chen CL, Feng TH and Juang HH:
Mucosa-associated lymphoid tissue 1 is an oncogene inducing cell
proliferation, invasion, and tumor growth via the upregulation of
NF-κB activity in human prostate carcinoma cells. Biomedicines.
9:2502021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knies N, Alankus B, Weilemann A, Tzankov
A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G and Ruland J:
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell
proliferation via cooperative NF-κB and JNK activation. Proc Natl
Acad Sci USA. 112:E7230–E7238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiba T, Soeno Y, Shirako Y, Sudo H,
Yagishita H, Taya Y, Kawashiri S, Okada Y and Imai K: MALT1
inhibition of oral carcinoma cell invasion and ERK/MAPK activation.
J Dent Res. 95:446–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adams E, Sepich-Poore GD,
Miller-Montgomery S and Knight R: Using all our genomes:
Blood-based liquid biopsies for the early detection of cancer. View
(Beijing). 3:202001182022.PubMed/NCBI
|
|
26
|
Wang L, Zhang M, Pan X, Zhao M, Huang L,
Hu X, Wang X, Qiao L, Guo Q, Xu W, et al: Integrative serum
metabolic fingerprints based multi-modal platforms for lung
adenocarcinoma early detection and pulmonary nodule classification.
Adv Sci (Weinh). 9:e22037862022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang J, Yin X, Zhang L, Zhang X, Lin Y,
Zhuang L, Liu W, Zhang R, Yan X, Shi L, et al: Defective Fe
metal-organic frameworks enhance metabolic profiling for
high-accuracy diagnosis of human cancers. Adv Mater.
34:e22014222022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamp I, O'Neill TJ, Plettenburg O and
Krappmann D: A patent review of MALT1 inhibitors (2013-present).
Expert Opin Ther Pat. 31:1079–1096. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Zhang G, Jin J, Degan S, Tameze Y
and Zhang JY: MALT1 promotes melanoma progression through JNK/c-Jun
signaling. Oncogenesis. 6:e3652017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang VC, Liu Y, Lian J, Huang S, Jordan
A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, et al: Cotargeting of BTK
and MALT1 overcomes resistance to BTK inhibitors in mantle cell
lymphoma. J Clin Invest. 133:e1656942023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McAuley JR, Bailey KM, Ekambaram P, Klei
LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, et al:
MALT1 is a critical mediator of PAR1-driven NF-κB activation and
metastasis in multiple tumor types. Oncogene. 38:7384–7398. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Sun G, Li X, Fu Z, Guo C, Cao G,
Wang B, Wang Q, Yang S, Li D, et al: Inhibition of MALT1
paracaspase activity improves lesion recovery following spinal cord
injury. Sci Bull (Beijing). 64:1179–1194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang D, Jiang Q, Ge X, Shi Y, Ye T, Mi Y,
Xie T, Li Q and Ye Q: RHOV promotes lung adenocarcinoma cell growth
and metastasis through JNK/c-Jun pathway. Int J Biol Sci.
17:2622–2632. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang T, Wu H, Lin M, Yin J, Tan L, Ruan Y
and Feng M: B4GALNT1 promotes progression and metastasis in lung
adenocarcinoma through JNK/c-Jun/Slug pathway. Carcinogenesis.
42:621–630. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo Z, Han Z, Shou F, Li Y and Chen Y:
LINC00958 accelerates cell proliferation and migration in non-small
cell lung cancer through JNK/c-JUN signaling. Hum Gene Ther
Methods. 30:226–234. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tanimura K, Yamada T, Horinaka M, Katayama
Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M,
et al: Inhibition of c-Jun N-terminal kinase signaling increased
apoptosis and prevented the emergence of ALK-TKI-tolerant cells in
ALK-rearranged non-small cell lung cancer. Cancer Lett.
522:119–128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Staal J, Driege Y, Bekaert T, Demeyer A,
Muyllaert D, Van Damme P, Gevaert K and Beyaert R: T-cell
receptor-induced JNK activation requires proteolytic inactivation
of CYLD by MALT1. EMBO J. 30:1742–1752. 2011. View Article : Google Scholar : PubMed/NCBI
|
